Flagship's latest boast? A startup that will 'revolutionize treatment' for 'ninety percent of human illness'
Christopher Austin has spent the last decade building a government agency known in part for helping change drug development for rare diseases. Now, he’d like to focus on the far more common ones.
On Wednesday Austin and the VC firm Flagship Pioneering announced the launch of — and a $75 million Series A for — Vesalius Therapeutics, a biotech that is trying to “revolutionize the treatment of the diseases that drive ninety percent of human illness,” according to a press release.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.